News
We send the latest information from SMC Laboratories.
Drug Efficacy Study in the STAM™ Model Published in Cells
SMC is proud to announce that Cellaïon (BEL) has published the results of their study using our STAM™ model in Cells. ■Title Human Allogeneic Liver-Derived Progenitor Cells Significantly Improve NAFLD Activity Score and Fibrosis in Late-Stage NASH Animal Model ( Najimi et al., Cells. 2022 ) In this study, the authors reported that…
Drug Efficacy Study in the STAM™ Model Published in Gene
SMC is proud to announce that TSUMURA & CO. (JPN) has published the results of their study using our STAM™ model in Gene. ■Title Integrated analysis of effect of daisaikoto, a traditional Japanese medicine, on the metabolome and gut microbiome in a mouse model of nonalcoholic fatty liver disease Ishizawa et al., Gene. 2022…
SMC participate The BioJapan Partnering!
We are pleased to announce that SMC Laboratories will be participating the BioJapan Partnering Event from October 12th (Wed) to 14th (Fri). BioJapan is Asia’s largest partnering event and offers attendees the opportunity to partake in many different exhibitions, seminars, and partnering programs, as well as hold face-to-face meetings at on-site exhibition booths. We would…
Today, September 21th, is World Alzheimer’s Day!
We recently mentioned World Alzheimer's Month, including World Alzheimer's Day (Previous article), and today we would like to share SMC's thoughts on the development of a medicine for the treatment of Alzheimer's disease. There are currently five FDA-approved drugs for Alzheimer's disease (Donepezil, Rivastigmine, Galantamine, Memantine, and Aducanumab). These treatments can be divided into…
The importance of the NAFLD activity score and the STAM™ model’s clinical relevance
In this issue, we would like to introduce the NAFLD activity score (NAS), which is one of the main endpoints used in the development of drug candidates for NASH, and the role it plays in our proprietary STAM™ model. But, first, what is NAS and how does it relate to the study of NASH?…
Introducing our Idiopathic Pulmonary Fibrosis (IPF) mouse model
The outbreak of COVID-19 causes a lot of complications and long-term harm to the patient, especially severe pulmonary fibrosis. We offer the Idiopathic Pulmonary Fibrosis (IPF) mouse model as a potential model for the development of therapeutics for lung fibrosis, and many of our customers have used this model through our introduction of its usefulness….
September is World Alzheimer’s Month!
In recognition of September 21st being World Alzheimer’s Day, why don’t we deepen our understanding of Alzheimer's disease? In 1994, the “Alzheimer's Disease International” (ADI), in collaboration with the World Health Organization (WHO), established September 21st as “World Alzheimer's Day” to raise awareness for people who suffer from dementia. In addition to this, September…
SMC attend The Biotechgate Digital Partnering!
We are pleased to announce that SMC Laboratories will be virtually attending the Biotechgate Digital Partnering from August 29th to September 2nd. We would love to have the opportunity to meet with you virtually and introduce ourselves and our preclinical models, so please join us! If you would like to discuss specific collaboration opportunities,…
SMC attend The 8th Taiwan-Japan Pharmaceutical Seminar/Business Matching!
We are pleased to announce that SMC Laboratories will be virtually attending the 8th Taiwan-Japan Pharmaceutical Seminar/Business Matching on September 2nd. So, you can conduct web meeting using Teams. If you are attending the event and are interested in our services or STAM™ mice, please feel free to contact us. Even if you do…
A study using liver samples from the STAM™ model published in PLOS ONE.
SMC is proud to announce that Institut de Recherches Servier (FRA) has published the results of their study using our STAM™ model liver samples in PLOS ONE. Title ”Procollagen C-Proteinase Enhancer-1 (PCPE-1) deficiency in mice reduces liver fibrosis but not NASH progression“ In this paper, the authors compared the extent to which C-Proteinase…